Noruega - norueguês - Statens legemiddelverk

unimedic pharma ab - metadonhydroklorid - mikstur, oppløsning med bringebærsmak - 90 mg

Noruega - norueguês - Statens legemiddelverk

unimedic pharma ab - metadonhydroklorid - mikstur, oppløsning med bringebærsmak - 120 mg

Noruega - norueguês - Statens legemiddelverk

unimedic pharma ab - metadonhydroklorid - mikstur, oppløsning med bringebærsmak - 130 mg

Noruega - norueguês - Statens legemiddelverk

unimedic pharma ab - metadonhydroklorid - mikstur, oppløsning med bringebærsmak - 140 mg

União Europeia - norueguês - EMA (European Medicines Agency)

taw pharma (ireland) limited - klopidogrelhydroklorid - peripheral vascular diseases; stroke; myocardial infarction; acute coronary syndrome - antithrombotic agents - , , , , secondary prevention of atherothrombotic events, , clopidogrel is indicated in: , - adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. , - adult patients suffering from acute coronary syndrome:,    - non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). ,     - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy. , , in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is), clopidogrel in combination with asa is indicated in:, - adult patients with moderate to high-risk tia (abcd2  score ≥4) or minor is (nihss  ≤3) within 24 hours of either the tia or is event.  , , prevention of atherothrombotic and thromboembolic events in atrial fibrillation, in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. , , for further information please refer to section 5. , , ,.

União Europeia - norueguês - EMA (European Medicines Agency)

teva pharma b.v. - pioglitazonhydroklorid - diabetes mellitus, type 2 - legemidler som brukes i diabetes - pioglitazone is indicated in the treatment of type-2 diabetes mellitus as monotherapy: , in adult patients (particularly overweight patients) inadequately controlled by diet and exercise for whom metformin is inappropriate because of contraindications or intolerance. , pioglitazone is also indicated for combination with insulin in type 2 diabetes mellitus adult patients with insufficient glycaemic control on insulin for whom metformin is inappropriate because of contraindications or intolerance. etter initiering av behandling med pioglitazon, pasienter bør vurderes etter 3 til 6 måneder for å vurdere tilstrekkeligheten av respons på behandling (e. reduksjon i hba1c). hos pasienter som ikke klarer å vise et adekvat svar, pioglitazon bør seponeres. i lys av potensiell risiko med langvarig behandling, prescribers bør bekrefte på følgende rutine anmeldelser dra nytte av pioglitazone er opprettholdt.

Noruega - norueguês - Statens legemiddelverk

unimedic pharma ab - metadonhydroklorid - mikstur, oppløsning med bringebærsmak - 15 mg

Noruega - norueguês - Statens legemiddelverk

unimedic pharma ab - metadonhydroklorid - mikstur, oppløsning med bringebærsmak - 20 mg

Noruega - norueguês - Statens legemiddelverk

unimedic pharma ab - metadonhydroklorid - mikstur, oppløsning med bringebærsmak - 25 mg

Noruega - norueguês - Statens legemiddelverk

unimedic pharma ab - metadonhydroklorid - mikstur, oppløsning med bringebærsmak - 35 mg